Avibactam/ceftazidime

Drug Profile

Avibactam/ceftazidime

Alternative Names: AVE 1330/ceftazidime; AVE 1330A/ceftazidime; AVYCAZ; CAZ 104; CAZ-AVI; Ceftazidime/AVE 1330; Ceftazidime/AVE 1330A; Ceftazidime/NXL 104; NXL 104/ceftazidime; Zavicefta

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Novexel
  • Developer Allergan; AstraZeneca; Cerexa; Novexel
  • Class Amides; Cephalosporins; Heterocyclic bicyclo compounds; Small molecules; Sulfates
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gram-negative infections; Intra-abdominal infections; Urinary tract infections
  • Registered Nosocomial pneumonia

Most Recent Events

  • 30 Jan 2017 US FDA approves sNDA for avibactam/ceftazidime to update the label with new phase III trial results for Urinary tract infections in January 2017
  • 12 Oct 2016 US FDA accepts sNDA to review for avibactam/ceftazidime to update the label with new phase III trial results for Urinary tract infections
  • 11 Oct 2016 Allergan files sNDA for avibactam/ceftazidime to update the label with new phase III trial results for Urinary tract infections before October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top